Expression of the lung resistance-related protein in human and rat hepatocarcinogenesis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 283, Issue 5 46-5, 2002, Pages

  Raidl, Maria ^a   Berger, Walter ^a   Schulte Hermann, Rolf ^a   Kandioler Eckersberger, Daniela ^b   Kappel, Sonja ^b   Wrba, Fritz ^b   Micksche, Michael ^a   Grasl Kraupp, Bettina ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemoresistance; Hepatocellular carcinoma; Human liver; Vault particle

Indexed keywords

LUNG RESISTANCE PROTEIN; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELL TRANSPORT; CHEMOREACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DYSPLASIA; EPITHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER NODULE; LUNG RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR PROMOTION;

EID: 0036840624     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00195.2002     Document Type: Article

References (42)

1. Bader P, Fuchs J, Wenderoth M, von Schweinitz D, Niethammer D, and Beck JF. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin. Anticancer Res 18: 3127-3132, 1998.
2. Berger W, Elbling L, and Micksche M. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 88: 293-300, 2000.
3. Berger W, Spiegl-Kreinecker S, Buchroithner J, Elbling L, Pirker C, Fischer J, and Micksche M. Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer 94: 377-382 2001.
4. Bosch FX, Ribes J, and Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 19: 271-285, 1999.
5. Bradley G, Sharma R, Rajalakshmi S, and Ling V. P-glycoprotein expression during tumor progression in the rat liver. Cancer Res 52: 5154-5161, 1992.
6. Cheng SH, Lam W, Lee AS, Fung KP, Wu RS, and Fong WF. Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution. Toxicol Appl Pharmacol 164: 134-142, 2000.
7. Chugani DC, Rome LH, and Kedersha NL. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 106: 23-29, 1993.
8. Courtois A, Payen L, Guillouzo A, and Fardel O. Up-regulation of multidrug resistance-associated protein 2 (MRP2) expression in rat hepatocytes by dexamethasone. FEBS Lett 459: 381-385, 1999.
9. Edmondson HA and Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,000 necropsies. Cancer 7: 462-503, 1954.
10. Fairchild CR, Ivy SP, Rushmore T, Lee G, Koo P, Goldsmith ME, Myers CE, Farber E, and Cowan KH. Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci USA 84: 7701-7705, 1987.
11. Farber E and Cameron R. The sequential analysis of cancer development. Adv Cancer Res 31: 125-226, 1980.
12. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, and Pastan I. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989.
13. Grasl-Kraupp B, Rossmanith W, Ruttkay-Nedecky B, Mullauer L, Kammerer B, Bursch W, and Schulte-Hermann R. Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia. Hepatology 28: 717-726, 1998.
14. Grasl-Kraupp B, Waldhor T, Huber W, and Schulte-Hermann R. Glutathione S-transferase isoenzyme patterns in different subtypes of enzyme-altered rat liver foci treated with the peroxisome proliferator nafenopin or with phenobarbital. Carcinogenesis 14: 2407-2412, 1993.
15. Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, McMaster P, and Kerr DJ. Hepatocellular carcinoma. Ann Oncol 12: 161-172, 2001.
16. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 22: 983-993, 1995.
17. Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P, and Scheper RJ. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 148: 877-887, 1996.
18. Jungermann K, and Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 31: 255-260, 2000.
19. Kauffmann HM, Keppler D, Kartenbeck J, and Schrenk D. Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Hepatology 26: 980-985, 1997.
20. Kedersha NL and Rome LH. Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 103: 699-709, 1986.
21. Keppler D and Arias IM. Hepatic canalicular membrane. Introduction: transport across the hepatocyte canalicular membrane. FASEB J 11: 15-18, 1997.
22. Kickhoefer VA, Siva AC, Kedersha NL, Inman EM, Ruland C, Streuli M, and Rome LH. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 146: 917-928, 1999.
23. Kickhoefer VA, Stephen AG, Harrington L, Robinson MO, Rome LH. Vaults and telomerase share a common subunit, TEP1. J Biol Chem 274: 32712-32717, 1999.
24. Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T, and Akiyama S. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91: 1647-1653, 1999.
25. Koepsell H. Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 60: 243-266, 1998.
26. Low-Baselli A, Huber WW, Kafer M, Bukowska K, Schulte-Hermann R, and Grasl-Kraupp B. Failure to demonstrate chemoprevention by the monoterpene perillyl alcohol during early rat hepatocarcinogenesis: a cautionary note. Carcinogenesis 21: 1869-1877, 2000.
27. Lucia M (Lucia G). Function Reference. Laboratory Imaging, Prague, Czechoslovakia, 1995
28. Lucia M (Lucia G). User's Guide. Laboratory Imaging, Prague, Czechoslovakia, 1995.
29. Meyer UA and Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37: 269-296, 1997.
30. Nakatsukasa H, Silverman JA, Gant TW, Evarts RP, and Thorgeirsson SS. Expression of multidrug resistance genes in rat liver during regeneration and after carbon tetrachloride intoxication. Hepatology 18: 1202-1207, 1993.
31. Payen L, Courtois A, Vernhet L, Guillouzo A, and Fardel O. The multidrug resistance-associated protein (MRP) is overexpressed and functional in rat hepatoma cells. Int J Cancer 81: 479-485, 1999.
32. Pitot HC. Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 30: 465-500, 1990.
33. Plaat BE, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, Hoekstra HJ, van den Berg E, Scheper RJ, and van der Graaf WT. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 18: 3211-3220, 2000.
34. Runge D, Kohler C, Kostrubsky VE, Jager D, Lehmann T, Runge DM, May U, Stolz DB, Strom SC, Fleig WE, and Michalopoulos GK. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 273: 333-341, 2000.
35. Satoh K, Kitahara A, Soma Y, Inaba Y, Hatayama I, and Sato K. Purification, induction, and distribution of placental glutathione transferase: a new marker enzyme for preneoplastic cells in the rat chemical hepatocarcinogenesis. Proc Natl Acad Sci USA 82: 3964-3968, 1985.
36. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, and Scheper RJ. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12: 550-556, 2000.
37. Schulte-Hermann R. Tumor promotion in the liver. Arch Toxicol 57: 147-158, 1985.
38. Silverman JA and Thorgeirsson SS. Regulation and function of the multidrug resistance genes in liver. Prog Liver Dis 13: 101-123, 1995.
39. Sugawara I, Akiyama S, Scheper RJ, and Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 112: 23-31, 1997.
40. Vessey DA. Metabolism of xenobiotics, 1996. In: Hepatology. A Textbook of Liver Disease, edited by Zakim D and Boyler TD. Philadelphia, PA: Saunders, 1996, p. 257-306.
41. Yusuf A, Rao PM, Rajalakshmi S, and Sarma DS. Development of resistance during the early stages of experimental liver carcinogenesis. Carcinogenesis 20: 1641-1644, 1999.
42. Zijlstra JG, de Vries EG, and Mulder NH. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47: 1780-1784, 1987.